Introduction: Thymic epithelial tumors (TETs) are rare malignancies associated with dysregulation of the immune system and humoral- and cell-mediated immunity abnormalities. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccine is effective in preventing coronavirus disease 2019 morbidity and mortality. The aim of this study was to evaluate the seroconversion in patients with TET after two doses of mRNA vaccine. Methods: This is a prospective study in which consecutive patients with TET were enrolled before receiving the first dose of SARS-CoV-2 mRNA vaccine (BNT162b2 by Pfizer-BioNTech). SARS-CoV-2 spike-binding immunoglobulin (Ig)G antibody serologic levels were analyzed at different time points, including before first vaccine dose (T0), 1 month after the second dose (T2), and 3 months after the second dose (T3). Results: Overall, 39 patients were included in the analysis. All patients had negative antibody titer results at T0. There were 19 patients (48.7%) in the follow-up with no residual tumor lesion/s (referred as no evidence of disease), and 20 (51.3%) had evidence of disease (ED) and were receiving systemic treatment. Dysregulations of the immune system were diagnosed in 29 patients (74.4%) with Good syndrome (GS) being the most frequent immune disorder (48.7%). At univariate analysis, lack of seroconversion at T2 was significantly associated with ED (p < 0.001) and with GS (p = 0.043). A significant association with impaired seroconversion was confirmed at multivariate analysis for ED (p = 0.00101) but not for GS (p = 0.625). Conclusions: Our data revealed that patients with TET with ED had substantially higher probability of impaired seroconversion after SARS-CoV-2 mRNA vaccine as compared with patients with no evidence of disease.

Impaired Seroconversion After Severe Acute Respiratory Syndrome Coronavirus 2 mRNA Vaccine in Patients With Thymic Epithelial Tumors / Pietroluongo, Erica; De Placido, Pietro; Tortora, Marianna; Martinelli, Claudia; Viggiano, Angela; Saponaro, Maria Rosaria; Caltavituro, Aldo; Buonaiuto, Roberto; Morra, Rocco; Ottaviano, Margaret; Del Deo, Vitantonio; Cernera, Gustavo; Gelzo, Monica; Malfitano, Anna Maria; Di Tolla, Michele Francesco; De Angelis, Carmine; Arpino, Grazia; Terracciano, Daniela; Bianco, Roberto; Veneziani, Bianca Maria; Formisano, Pietro; Castaldo, Giuseppe; Palmieri, Giovannella; De Placido, Sabino; Giuliano, Mario. - In: JOURNAL OF THORACIC ONCOLOGY. - ISSN 1556-1380. - (2023). [10.1016/j.jtho.2023.06.015]

Impaired Seroconversion After Severe Acute Respiratory Syndrome Coronavirus 2 mRNA Vaccine in Patients With Thymic Epithelial Tumors

Pietroluongo, Erica;De Placido, Pietro;Martinelli, Claudia;Viggiano, Angela;Saponaro, Maria Rosaria;Caltavituro, Aldo;Morra, Rocco;Ottaviano, Margaret;Cernera, Gustavo;Gelzo, Monica;Malfitano, Anna Maria;Di Tolla, Michele Francesco;De Angelis, Carmine;Arpino, Grazia;Terracciano, Daniela;Veneziani, Bianca Maria;Formisano, Pietro;Castaldo, Giuseppe;Palmieri, Giovannella;De Placido, Sabino;Giuliano, Mario
2023

Abstract

Introduction: Thymic epithelial tumors (TETs) are rare malignancies associated with dysregulation of the immune system and humoral- and cell-mediated immunity abnormalities. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccine is effective in preventing coronavirus disease 2019 morbidity and mortality. The aim of this study was to evaluate the seroconversion in patients with TET after two doses of mRNA vaccine. Methods: This is a prospective study in which consecutive patients with TET were enrolled before receiving the first dose of SARS-CoV-2 mRNA vaccine (BNT162b2 by Pfizer-BioNTech). SARS-CoV-2 spike-binding immunoglobulin (Ig)G antibody serologic levels were analyzed at different time points, including before first vaccine dose (T0), 1 month after the second dose (T2), and 3 months after the second dose (T3). Results: Overall, 39 patients were included in the analysis. All patients had negative antibody titer results at T0. There were 19 patients (48.7%) in the follow-up with no residual tumor lesion/s (referred as no evidence of disease), and 20 (51.3%) had evidence of disease (ED) and were receiving systemic treatment. Dysregulations of the immune system were diagnosed in 29 patients (74.4%) with Good syndrome (GS) being the most frequent immune disorder (48.7%). At univariate analysis, lack of seroconversion at T2 was significantly associated with ED (p < 0.001) and with GS (p = 0.043). A significant association with impaired seroconversion was confirmed at multivariate analysis for ED (p = 0.00101) but not for GS (p = 0.625). Conclusions: Our data revealed that patients with TET with ED had substantially higher probability of impaired seroconversion after SARS-CoV-2 mRNA vaccine as compared with patients with no evidence of disease.
2023
Impaired Seroconversion After Severe Acute Respiratory Syndrome Coronavirus 2 mRNA Vaccine in Patients With Thymic Epithelial Tumors / Pietroluongo, Erica; De Placido, Pietro; Tortora, Marianna; Martinelli, Claudia; Viggiano, Angela; Saponaro, Maria Rosaria; Caltavituro, Aldo; Buonaiuto, Roberto; Morra, Rocco; Ottaviano, Margaret; Del Deo, Vitantonio; Cernera, Gustavo; Gelzo, Monica; Malfitano, Anna Maria; Di Tolla, Michele Francesco; De Angelis, Carmine; Arpino, Grazia; Terracciano, Daniela; Bianco, Roberto; Veneziani, Bianca Maria; Formisano, Pietro; Castaldo, Giuseppe; Palmieri, Giovannella; De Placido, Sabino; Giuliano, Mario. - In: JOURNAL OF THORACIC ONCOLOGY. - ISSN 1556-1380. - (2023). [10.1016/j.jtho.2023.06.015]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/936288
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 3
social impact